Milestone Asset Management LLC Purchases 7,513 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Milestone Asset Management LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 50.9% in the 4th quarter, Holdings Channel reports. The fund owned 22,277 shares of the biopharmaceutical company’s stock after buying an additional 7,513 shares during the quarter. Milestone Asset Management LLC’s holdings in Gilead Sciences were worth $2,058,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in GILD. Avior Wealth Management LLC lifted its holdings in shares of Gilead Sciences by 1.2% during the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after purchasing an additional 108 shares in the last quarter. Southland Equity Partners LLC raised its position in Gilead Sciences by 3.6% in the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 110 shares during the last quarter. Concord Asset Management LLC VA raised its position in Gilead Sciences by 3.8% in the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 111 shares during the last quarter. Berkshire Bank raised its position in Gilead Sciences by 3.4% in the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock worth $314,000 after buying an additional 111 shares during the last quarter. Finally, TFB Advisors LLC raised its position in Gilead Sciences by 1.2% in the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock worth $788,000 after buying an additional 116 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on GILD. Cantor Fitzgerald reissued a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research report on Wednesday, December 11th. Oppenheimer boosted their target price on Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. The Goldman Sachs Group boosted their target price on Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Morgan Stanley raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $87.00 to $113.00 in a research report on Friday, January 10th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $98.39.

Gilead Sciences Stock Up 1.9 %

Shares of GILD opened at $95.59 on Thursday. The company has a market cap of $119.13 billion, a PE ratio of 1,062.11, a P/E/G ratio of 1.31 and a beta of 0.18. The business has a fifty day moving average of $92.00 and a 200 day moving average of $85.44. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s revenue was up 7.0% on a year-over-year basis. During the same period last year, the company earned $2.29 earnings per share. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the sale, the insider now owns 80,801 shares in the company, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock worth $42,130,461 over the last three months. 0.16% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.